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Abstract
Research and development activities have become more and more internationalized with emerging
economies playing an increasingly important role. This phenomenon is particularly debated in the
pharmaceutical industry where (Western) pharmaceutical companies have started to offshore clinical
research to so-called nontraditional clinical research countries. This study empirically investigates the
changing geography of clinical research between the years 2002 and 2012. Building on the concept of
national innovative capacity (Furman et al., 2002, Res. Policy, 31, 899–933), we shed light on different
drivers of countries’ attractiveness as a location for clinical research including arguments related to
the supply (cost)-side, the demand-side, and the knowledge base. Our results challenge existing views
on the extent of the phenomenon as well as the involvement of particular countries. Across nontradi-
tional countries, the level of clinical research activities is driven by knowledge rather than cost argu-
ments. Moreover, the rising strength of the knowledge base of nontraditional countries enables them
to increasingly direct research in favor of local needs.
JEL classification: F63, L65, O19, O32
1. Introduction
The geographical distribution of several aspects of economic activity has changed tremendously in the past decades.
Ideas, new products, and technology are spreading faster than ever all over the world. Individuals in developing
countries—formerly quite isolated—are more likely to have fast access to new (technological) developments and
products. However, there is an ongoing controversy whether globalization increases prosperity for all humans or
whether it exacerbates the split between rich and poor, even leading to the exploitation of the population and re-
sources of less-privileged countries. This debate is particularly fueled in terms of the pharmaceutical industry.
Concurrently, it has been observed that emerging and developing economies play an increasingly important role
in conducting clinical trials (Thiers et al., 2008; Belforti et al., 2010), although the economic and ethical conse-
quences of this development are by no means clear and have been controversially debated (Nundy and Gulhati,
2005; Lang and Siribaddana, 2012). These new locations for clinical trials have been labeled as nontraditional coun-
tries. This terminology is based upon the, until recently, rather strong concentration of the industry’s preclinical and
clinical research and development (R&D) activities in its “traditional centers” in North America, Western Europe,
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and a few other locations in the Asia-Pacific region, such as Japan, Australia, and New Zealand (Thiers et al., 2008;
Glickman et al., 2009). Interestingly, so far the evidence about the changing landscape of clinical research is mostly
anecdotal, which has led to contradictory views about the involvement of particular countries, the underlying reasons
for the phenomenon, and its consequences for the involved locations.
In this article, our objective is to shed light on the involvement of nontraditional countries in clinical research
activities. Accordingly, we build on the national innovative capacity framework (Furman et al., 2002) to examine the
drivers of the involvement in clinical research activities across nontraditional countries. Following this concept, we
consider supply-side arguments emphasizing lower costs, the increasing attractiveness of markets, as well as the rising
knowledge base of countries and their impact on the number as well as the types of clinical trials performed in
nontraditional countries. By focusing on the country-level, we account for the importance of national institutions
and differences in national innovative capacities (Henderson et al., 1999). A comprehensive data set of all registered
clinical trials in the ClinicalTrials.gov database between January 2002 and December 2012 allows us to map interna-
tionalization patterns, identify stylized facts, and provide explanations for the observed developments.
Our findings suggest increasing clinical research activities in many nontraditional countries but with a large het-
erogeneity. While India is often named as the main destination for offshored clinical trials, the number of trials actu-
ally conducted in India increased only slightly. In contrast, the number of clinical trials performed in South Korea
and China has accelerated. In terms of the drivers of this development related to countries’ national innovative cap-
acity, our analysis revealed that supply-related drivers have very limited explanatory power. The growth of clinical
research activities in nontraditional countries is driven by knowledge-intense Phase 2 trials and not by data-generat-
ing and cost-intense Phase 3 trials.
Further, we extend the range of applications of the national innovative capacity framework by investigating the
direction of R&D activities. More precisely, we map the similarity between nontraditional countries’ clinical trial
profiles and the US profile. We find no general pattern of convergence. Most interestingly, countries with a strong do-
mestic science base—presumably spurred by learning from prior (offshored) trials—increasingly conduct clinical re-
search corresponding to local health problems. In contrast, countries with more attractive domestic markets tend to
be locations for clinical research focusing on disease areas with a global prevalence.
Our results challenge existing views and widely held beliefs among academics, policy makers, and industry ex-
perts concerning the changing geography of clinical trials. The results have important implications for the design of
policies aiming at strengthening the national innovative capacity and at addressing the specific needs of host coun-
tries. Furthermore, our results call into question the relevance of cost-related factors for the internationalization of
R&D activities.
The remainder of the article is structured as follows: Section 2 introduces the reader to the national innovative
capacity literature and the drivers for changing global R&D particularly in pharmaceuticals. Section 3 describes the
data, measures, and methods used in the empirical analysis. Section 4 provides the empirical analysis, and Section 5
offers conclusions.
2. Arguments for the changing geography of clinical trials
In the past decades, R&D activities have become increasingly internationalized and have shifted towards emerging
economies. In turn, emerging economies have become better connected to international networks in science and
R&D (Wagner and Leydesdorff, 2005; Cantner and Rake, 2014). Nevertheless, there are remarkable differences
among emerging economies. Some countries, particularly China and India, have become more embedded in interna-
tional R&D activities than others (United Nations Conference on Trade and Development, 2005; Thursby and
Thursby, 2006).
Differences in the involvement of particular countries in global R&D networks can be at least partly explained by
differences in countries’ national innovative capacity, i.e., their long-term ability to produce commercially relevant
innovations (Porter and Stern, 2001; Furman et al., 2002; Hu and Mathews, 2005). This literature highlights three
main country-specific factors. First, differences among countries can be traced back to country-specific supply-side
factors such as the innovation infrastructure related to the political environment, the stock of scientific and techno-
logical knowledge, as well as the availability of human capital and financial resources (Varsakelis, 2006; Fagerberg
and Srholec, 2008). Second, domestic demand is an important factor shaping the rate and direction of innovation
activities (Porter and Stern, 2001; Furman et al., 2002). Third, the strength of linkages between a country’s common
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innovation infrastructure and its industrial clusters influence the extent to which its national innovative capacity can
be translated into innovative outcomes. The absence of strong linkages within a country may lead to spillovers to
other countries (Furman et al., 2002). For emerging economies, these spillovers provide opportunities to enhance
their national innovative capacity through the transfer of scientific and technological knowledge from developed
economies (Liu and Buck, 2007).
We consider the concept of national innovative capacity to be useful for analyzing the changing geography of
R&D activities for two reasons. First, it describes a country’s attractiveness as a location for offshored R&D activ-
ities depending on supply- and demand-side factors. Second, it can be transferred to our setting of trials-based re-
search and the catch-up of emerging countries. Even though these countries may lag behind the scientific and
technological frontier, they benefit from linkages with advanced economies.
In the following, we outline supply-side, demand-side as well as arguments in terms of countries’ knowledge bases
as potential drivers of the changing geography of R&D activities in general and of clinical research activities in
particular.1
2.1 Supply-side arguments
With respect to supply-side factors, the realization of cost advantages through the internationalization of manu-
facturing can be seen as a role model for the geographical expansion of R&D activities to emerging economies,
particularly for activities sensitive to R&D costs (United Nations Conference on Trade and Development, 2005;
Demirbag and Glaister, 2010). One stream of literature argues that these cost advantages are strongly related to
the availability of R&D inputs such as highly skilled science and engineering staff that have become increasingly
scarce in developed countries. Thus, emerging economies with a large supply of human capital, particularly sci-
ence and engineering talent, are attractive locations for offshored R&D activities (Florida, 1997; Manning
et al., 2008; Lewin et al., 2009). Kumar (2001) reports that the availability of R&D personnel as well as the
level of scientific and technological advancement improves the chances of a country of attracting R&D activ-
ities. Nonetheless, countries with a generally lower level of scientific and technological advancement may still
become important providers of specific niche capabilities, e.g., specific scientific or technological knowledge
(Thomson, 2013).
In the context of the pharmaceutical industry, supply-side arguments are associated with the emergence of an-
other player in the value chain: research service providers. Since the mid-1980s, pharmaceutical companies contract
out specific clinical research activities, particularly monitoring, data management, and other noncore activities, to
specialized contract research organizations (CROs) which manage the key operational aspects of clinical
trials (Rettig, 2000; Azoulay, 2004; Howells et al., 2008). The involvement of CROs in clinical research allows
pharmaceutical companies to adjust their organizational boundaries: they keep knowledge-intensive tasks, which are
critical for a competitive advantage in-house, while outsourcing the coordination of data-intensive tasks (Azoulay,
2004).
It is widely noted and controversially debated that pharmaceutical firms offshore clinical trials to nontraditional
clinical trial countries to realize considerable cost advantages and access huge, well-trained, and often English-speak-
ing workforces (Maiti and Raghavendra, 2007; Petryna, 2007, 2009; Agalew, 2013; Haakonsson et al., 2013).2
Moreover, nontraditional countries have developed a comprehensive research and health care infrastructure over
time, including flagship facilities which are able to compete with their counterparts located in traditional countries
(Maiti and Raghavendra, 2007; Crone, 2008). Another important aspect in the choice of clinical trial locations is the
availability of a sufficient number of subjects willing to participate in clinical trials, since the efficiency of clinical re-
search depends largely on the number of enrolled subjects (Petryna, 2007; Haakonsson et al., 2013). Nontraditional
1 Beyond these arguments discussed below, international agreements like the agreement on Trade-Related Aspects of
Intellectual Property Rights and memberships in international organizations such as the World Trade Organization led to
the introduction of product patents for pharmaceutical products providing the industry standard protection mechanism
against imitation of drug candidates under development which can be seen as an enabling factor for offshoring of (clin-
ical) research activities (Kyle and McGahan, 2012).
2 As described in Section 1, nontraditional countries are those locations that have until recently not been involved in the
industry’s preclinical and clinical R&D activities (Thiers et al., 2008; Glickman et al., 2009).
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countries provide a high number of “treatment naı¨ve” individuals who have not been treated with a particular drug
or drug class before. Access to such individuals is very advantageous, since it is less probable that there will be unin-
tended interactions among different drugs. Moreover, as uncontrolled factors which could potentially influence the
study are reduced, the probability that a drug candidate shows a statistically significant effectiveness increases
(Petryna, 2009). In addition, the comparatively high supply of trial subjects can reduce the cost of clinical research
considerably and may influence the success of clinical trials in terms of the time needed for study completion
(Petryna, 2009).
2.2 Demand-side arguments
In contrast to supply-side arguments, a broad literature suggests that countries’ attractiveness as locations for offsh-
ored R&D activities may be particularly shaped by the size of local demand. Theoretical and empirical research on
the subject matter suggests that the need to adapt products for local markets and local manufacturing may drive the
location of R&D facilities abroad (Ha˚kanson and Nobel, 1993; Dunning, 1994; Odagiri and Yasuda, 1996; Patel
and Vega, 1999). Accordingly, countries with larger markets or fast-growing markets may have advantages in at-
tracting offshored R&D (Gassmann and Han, 2004). These demand-side patterns of R&D location may be of par-
ticular importance in the pharmaceutical industry where the rate and the direction of innovative activities are
generally largely shaped by (potential) market size (Acemoglu and Linn, 2004).
Nontraditional trial countries became more attractive as markets for (Western) pharmaceuticals, since the steady
economic growth in many of these countries has led to the emergence of broader high- and middle-income classes.
This development is accompanied by the development of health care provision, health insurance, and potential de-
mand for (Western) pharmaceuticals (Epstein, 2007). Moreover, economic growth and increasing wealth have led to
changes in local health problems caused by a different way of living and environmental impacts (Uusitalo et al.,
2003).
The global spread of many diseases, such as cancer, cardiovascular, and metabolic diseases, requires global clin-
ical trials to account for different disease environments caused by geographical and economic factors and to ensure
that benefits for the inhabitants of nontraditional clinical trial countries exist (Lanjouw and Cockburn, 2001;
Kremer, 2002; Lanjouw, 2006; Glickman et al., 2009). Besides the increasing market attractiveness of emerging
countries, also for medications that address diseases with a worldwide prevalence, there is a need for clinical trials
taking into account the specificities in the genetic constitution of local populations that can affect the safety and effi-
cacy of medications (Evans and Relling, 1999; Wilson et al., 2001).
2.3 Knowledge base arguments
While supply-side and demand-side factors mostly center on whether a country is attractive for offshored R&D activ-
ity, knowledge base arguments mainly consider the internal innovation capacity of a country. As such they focus on
the point of view of a specific (emerging) country rather than the offshoring decision of a firm in a developed country.
Countries may enhance their national innovative capacity through a range of innovation-oriented policies and sus-
tained investments, such as investments in their human capital (Furman and Hayes, 2004). Moreover, they can bene-
fit from knowledge spillovers particularly if scientifically and technologically more advanced countries cannot fully
translate their innovative capacity into innovative activities (Furman et al., 2002; Liu and Buck, 2007). Prior studies
suggest that particularly FDI and offshored R&D activities transfer skills and knowledge to host countries (Reddy,
1997; van Pottelsberghe de la Potterie and Lichtenberg, 2001; Smarzynska Javorcik, 2004). Host countries’ innova-
tive capacity may particularly benefit if learning is sufficiently easy, i.e., the geographical distance between local
actors and multinational companies’ R&D centers is sufficiently close to enable knowledge spillovers, and host coun-
try actors pursue own R&D activities (Hu et al., 2005; Qu et al., 2013). Nevertheless, it cannot be taken for granted
that host countries benefit from offshored R&D. Instead, literature on FDI spillovers suggests that particularly coun-
tries with a rather low gross domestic product (GDP) per capita and those with a rather high GDP per capita can
benefit from spillovers. The same applies to institutional factors, like economic freedom, and science or technology
indicators, like R&D expenditures and patenting (Meyer and Sinani, 2009).
From the perspective of the host countries, there are compelling learning arguments which increase their interest
to insource clinical trials. Patients in emerging countries often suffer from diseases which differ from those prevalent
in western countries. However, the rather small market size as well as a limited access to health care and health
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insurance has made it quite unattractive for (Western) pharmaceutical companies to develop new pharmaceuticals
addressing specific disease patterns prevalent in nontraditional countries (Lanjouw and Cockburn, 2001; Yip and
Mahal, 2008; Chaudhuri, 2010). The number of new drugs against tropical diseases has been quite limited through-
out the past decades, and pharmaceutical innovation has not yet decreased the burden of disease in developing coun-
tries (Pecoul et al., 1999; Lichtenberg, 2005).
Hence, such countries have a strong interest in developing a local knowledge base that enables its researchers to
develop new medications or to improve and adjust existing medications for local needs. The offshoring of clinical tri-
als provides an opportunity to enhance the national innovative capacity through knowledge spillovers, since particu-
larly Phase 1 and Phase 2 trials focus on the generation of new knowledge through the development and the testing
of hypotheses (Azoulay, 2004). To generate new knowledge, researchers often have to apply tacit knowledge from
different disciplines (Cockburn and Henderson, 2001; Malterud, 2001). In such settings, knowledge transfer and
learning occur predominantly through collaboration and joint clinical research activities between researchers
embedded in professional networks that allow for the transfer of complex, tacit, and private knowledge, also ena-
bling learning from peers (Reagans and McEvily, 2003; Uzzi and Lancaster, 2003). Since pharmaceutical R&D is
characterized by substantial spillovers between projects, knowledge acquired through joint clinical research projects
may be valuable in a wide range of subsequent projects (Cockburn and Henderson, 1996). Hence, the offshoring of
clinical research raised expectations that nontraditional countries could enhance their national innovative capacity
through an active participation of domestic scientists in clinical research projects originating in traditional countries.
For example, the government of India relaxed the regulation of clinical trials to support domestic clinical research
and participation in multinational trials in the hope of transforming the domestic pharmaceutical industry into an
“innovative leader” (Pharmaceutical Research & Development Committee, 1999).
In contrast to expectations, however, it appeared difficult for nontraditional countries to reap the potential bene-
fits from participating in clinical trials. While the enrollment of subjects from nontraditional countries increased in
recent years, the involvement of researchers from those countries remained quite modest. Hoekman et al. (2012)
show that authors from nontraditional countries are at best modestly involved in the production of scientific know-
ledge, particularly in industry-sponsored trials. This situation may limit the potential for learning and knowledge
spillovers and contradict the expectations raised by local authorities. Additionally, the potential benefits from offsh-
ored clinical trials are limited by (Western) pharmaceutical companies’ preference to conduct data-intensive trials
that have a lower potential for knowledge spillovers and learning outside firm boundaries (Azoulay, 2004).
3. Clinical trials data
We used the ClinicalTrials.gov3 database, a comprehensive registry of clinical trials maintained by the US National
Library of Medicine at the National Institutes of Health, to obtain detailed information on clinical studies conducted
in the United States and 179 other countries. Different parties are involved in conducting clinical trials, each one
with specific tasks and obligations. The (lead-)sponsor initiates and finances the clinical trial. The sponsor is most
often involved in the trial design and data analysis but not necessarily in conducting it. Clinical trials are often per-
formed in different types of facilities, commonly labeled as sites, including academic medical centers, private prac-
tices, community hospitals, or even dedicated, for-profit research centers (Azoulay, 2004). Particularly late-phase
clinical trials are often conducted in multiple facilities in different regions and countries at the same time to facilitate
the enrollment of a sufficient number of subjects. If market approval in various parts of the world is targeted, the
sponsors have to ensure that the sample population corresponds to the population in these markets to ensure the
safety and efficacy of the drug candidate for different ethnic groups and different ways of living. Each facility follows
a predefined protocol developed by the sponsor, the principal investigator, or by a contract research organization.
The latter ones offer clinical trial management services such as assistance in developing the trial protocol, in selecting
principal investigators and sites, in subject recruitment, as well as in analyzing and reporting the trial results (Rettig,
2000). Nevertheless, sponsors or principal investigators, i.e., the individuals who are responsible and accountable for
conducting a specific clinical trial, are usually in charge of submitting the required information to the trial registry
and keeping the information up to date.
3 http://clinicaltrials.gov/ct2/home.
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The database provides detailed information on each clinical trial including its design, its sponsors, the facilities
where it is conducted, and the disease or condition that it addresses as indicated by the Medical Subject Headings
(MeSH). With MeSH, the US National Library of Medicine provides a controlled vocabulary thesaurus for indexing
scientific biomedical research, e.g., journal articles.4 Clinical trials in our sample contain information on the corres-
ponding MeSH terms to indicate which conditions, diseases, treatments, or pathogens the trial addresses. MeSH
terms are organized using an alphabetical as well as a hierarchical structure called trees. At the most general level,
subject headings cover very broad terms such as “Neoplasms” that correspond to a three-digit identification or tree
number (e.g., C04 in case of “Neoplasms”). More specific subject headings are assigned to more detailed tree num-
bers, e.g., “Cysts” (C04.182) and “Bone Cysts” (C04.182.089). Each subject heading can be assigned to one or more
tree numbers. In the case of “Bone Cysts” two tree numbers have been assigned, C04.182.089 and C05.116.070.
The latter one indicates that bone cysts are a musculoskeletal, and particularly a bone disease. For each clinical trial
in our data set, we assign tree numbers that correspond to the MeSH term.
The database includes investigational, observational, and expanded access studies. In investigational studies, i.e.,
clinical trials in a narrow sense, the enrolled subjects receive none, one, or more diagnostic or therapeutic interven-
tions according to the study protocol so that the effects of the interventions on their health outcomes can be eval-
uated. Subjects enrolled in observational studies may receive a particular intervention, but they are not assigned to
this intervention by the investigator. Expanded access refers to a FDA-regulated process that allows for the provision
of investigational new drugs to patients with serious diseases who are not eligible for clinical trials.
Mandatory registration of clinical trials has been extended since the establishment of ClinicalTrials.gov on
February 29, 2000. In March 2002, the FDA published guidelines explaining statutory requirements for information
submissions and their implementation (Food and Drug Administration, 2002). Since then, studies addressing life-
threatening diseases have to be registered in addition to trials funded by the US government. The Food and Drug
Administration (2002, p. 4) defines life-threatening as “diseases or conditions where the likelihood of death is high
unless the course of the disease is interrupted” and as “diseases or conditions with potentially fatal outcomes, where
the endpoint of clinical trial analysis is survival.” The guidelines list the acquired immunodeficiency syndrome as
well as all other stages of human immunodeficiency virus infections, Alzheimer’s disease, angina pectoris, heart fail-
ure, and cancer as examples for life-threatening diseases. Moreover, chronic diseases such as inflammatory bowel dis-
ease, asthma, rheumatoid arthritis, diabetes mellitus, systemic lupus erythematosus, depression, and psychoses are
described as being serious in the sense of the US clinical research legislation at least during some stages of the course
of the diseases, or for certain populations.
The guidelines and laws dealing with clinical trial registration have been continuously updated and adjusted in re-
cent years. Following today’s legislation and with an exception for very early stage trials (Phase 1), each clinical trial
of drugs or biological products has to be registered if at least one trial site is located in the United States, if drug can-
didates are manufactured in the United States, or if the trial is conducted under an FDA investigational new drug ap-
plication (Food and Drug Administration, 2004; US Public Law 110-85, 2007). Hence, registration does not depend
on the country of origin of the sponsor but rather on the locations where the trial is conducted, the drug candidate is
manufactured, or whether the United States is the target market.5 Registration of clinical trials at ClinicalTrials.gov
may be subject to (manual) review to identify possible errors, deficiencies, or inconsistencies in the information pro-
vided by the responsible parties that were not detected by automatic checks during the submission process.
Noncompliance with the rules of clinical trial registration can lead to public notice of noncompliance, loss of NIH
4 https://www.nlm.nih.gov/pubs/factsheets/mesh.html.
5 As compared to other databases, e.g., the WHO Trial Registration Data Set, a meta-registry offered by the World Health
Organization, ClinicalTrials.gov offers very detailed information concerning the facilities where the trial is actually con-
ducted. However, the database does not cover all clinical trials that are conducted worldwide. In particular, it may not
cover trials that are not conducted in the United States testing drug candidates that are not manufactured in the United
States without an intention by the sponsor to get market approval in the United States. Based on registration require-
ments in ClinicalTrials.gov database, we expect that the database offers a reliable but conservative estimate of the role
of nontraditional countries in global clinical research.
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funding, and civil monetary penalties of up to $10,000 per day until the violation has been corrected (US Public Law
110-85, 2007).6
In addition to these regulations and guidelines, the International Committee of Medical Journal Editors (ICMJE)
has made clinical trial registration a precondition for publication to enable all interested stakeholders to explore the
full range of clinical evidence (Angelis et al., 2004). The ICMJE requires the registration of clinical trials in all phases
of the drug development process, including the early ones, even though it does not require registering trials in any
particular database (Wood, 2009). However, the registry has to meet some minimum requirements with respect to
the accessibility, the information provided, opportunities to search the database, and the mechanism to ensure the
validity of the data (Angelis et al., 2004).
When ClinicalTrials.gov was established in the year 2000, it was not immediately clear for which trials registra-
tion was mandatory or optional. This issue had been considerably clarified by the 2002 FDA guidelines. Therefore,
we exclude all trials that started before the year 2002 from our sample. The remaining sample encompasses 122,123
clinical trials that started between January 2002 and December 2012. For 112,194 of those clinical trials, we could
identify whether they are conducted in facilities located in the United States or in one of the 179 “other” countries.
In terms of “other” countries, 151 can be classified as nontraditional countries for conducting clinical trials.
Following Thiers et al. (2008), nontraditional countries for clinical trials are those that are neither located in North
America nor in Western Europe. Furthermore, Australia, Japan, and New Zealand can be seen as traditional clinical
trial countries. The acceptance of data generated in clinical trial facilities and in clinical trials conducted outside the
United States is important for the approval of new pharmaceuticals. While the acceptance of data generated in trad-
itional countries is without debate, trials conducted in nontraditional countries might be more controversial. The
FDA accepts data in its approval process if it stems from adequate, well-controlled clinical trials that are conducted
in compliance with the standards of good clinical practice and if the data are applicable to the US population (Khin
et al., 2013).
Most clinical trials are multicenter trials, i.e., they are conducted in different facilities and across different coun-
tries. We use information about the facilities of a trial to determine which countries are involved in a particular clin-
ical trial by calculating the number of clinical trials per country using fractional counting of trials. Information on
the lead sponsors of clinical trials is used to assign each lead sponsor to its country of origin. Since the database does
not provide a unique identifier for sponsoring organizations and contains lots of different name variants of one and
the same organization, we manually assigned the country of origin to all lead sponsors that were responsible for four
or more clinical trials. More precisely, we assigned the country of origin to 3567 lead sponsors that sponsor in sum
112,192 (91.87%) of the clinical trials in our sample. In total, 9931 clinical trials (8.13%) list a lead sponsor of a
nontraditional country.
Our data contain clinical trials in all phases of the gradual clinical development process of new pharmaceuticals.
Phase 0 trials include exploratory and microdose studies aiming at collecting early evidence whether the drug candi-
date acts in humans as anticipated in preclinical research. Phase 1 trials are usually conducted with healthy volunteers
to assess the safety of a drug candidate and to identify the most frequent and most serious adverse events.7
Furthermore, clinical trials in Phase 1 are frequently conducted to get insights into how the drug candidate is metabo-
lized and excreted. Phase 2 studies test drug candidates in humans who are affected by specific diseases or conditions
to obtain preliminary data on a drug candidate’s effectiveness. Trial subjects who receive the drug candidate can be
compared with similar subjects who receive a pharmacologically inactive substance or with those receiving a different
drug, mostly the standard of care. Safety evaluation continues, and short-term adverse events are studied. Put differ-
ently, Phase 2 clinical trials are used to study drug candidates in specific disease settings to obtain enough informa-
tion concerning the efficacy in that particular case. Based on this information, sponsors of clinical trials have to
decide whether to continue with Phase 3 trials. Phase 3 trials employ larger sample sizes to evaluate the safety and ef-
ficacy within different populations and by using different dosages. Phase 4 studies are conducted after market
6 It is important to note that most studies criticizing the completeness of the data reported in ClinicalTrials.gov focus their
critics not on registration of data but on whether results of clinical trials are made available through the database or in
scientific publications (Prayle et al., 2012). This study, however, does not take the clinical trial results and their reporting
into account.
7 Clinical trials addressing cancer are a notable exception. Due to the severe and harmful side effects of cancer drugs,
Phase 1 trials are conducted with patients that are affected by the disease (Azoulay, 2004).
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approval to gather additional information concerning a drug’s safety, efficacy, and its optimal use. Hence, there are
important differences between trial phases with respect to their importance for knowledge generation. While the gen-
eration and testing of hypotheses play an important role in clinical research up to Phase 2, trials from Phase 3 onward
focus on the generation of empirical evidence proving the effectiveness of the drug candidate against a placebo or the
existing standard of care. Consequently, we can assume that the importance of knowledge generation activities de-
creases relative to the progress of data generation activities and of the clinical research process (Azoulay, 2004).
In the data set used in this study, 802 clinical trials are assigned to Phase 0, 14,110 to Phase 1, 21,893 to Phase 2,
16,754 to Phase 3, and 13,732 to Phase 4. Moreover, for 47,273 clinical trials in our data set information concerning
the phase is missing while 7559 are assigned to multiple phases.
4. Empirical analysis
4.1 The changing geography of clinical trials over time
The following section maps the geography of trials over time in 11 nontraditional countries which can be found
among the 30 countries with the highest number of weighted clinical trials.8 We use the number of weighted clinical
trials per country i (Weighted Trialsit), i.e., each trial is weighted by the number of countries it is performed in, to ac-
count for the contribution of a particular country in conducting a trial depending on the number of other countries
involved. In doing so, we ensure that our results are neither driven by particular trials conducted in a large number of
facilities in multiple countries nor by trials that are exclusively conducted in one country.
We observe a general trend across countries that the number of clinical trials which started in a specific year has
been rising over time, from approximately 3900 in 2002 to more than 14,200 in the year 2012. While the United
States is the leading country involved in 40–50% of clinical trials conducted globally, our analysis focuses on the de-
velopment of clinical research activities in nontraditional clinical trial countries. China, South Korea, and Israel are
the leading nontraditional countries. Their position can partly be explained by the strength of their domestic
biopharmaceutical industry, the current or future importance of their markets, and governmental policies dedicated
to the support of R&D investments as well as scientific and technological catch-up (Barki, 2005; Kroll et al., 2008;
Liu et al., 2011; Wang et al., 2012).
Figure 1. Number of weighted clinical trials in selected nontraditional countries.
8 Table A1 in the Appendix provides an overview of countries conducting the highest number of weighted clinical trials
throughout our period of observation. We did not include Singapore and Greece in the descriptive analysis, since these
two countries may be rather similar to traditional countries for clinical research.
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Figure 1 shows that the nontraditional among the leading clinical trial countries have been able to increase the
total (weighted) number of clinical trials over time. Nevertheless, we observe considerable differences among these
countries. Particularly China, South Korea, and Israel managed to steadily increase the number of clinical trials. In
the year 2002, less than 32 trials started in Chinese facilities with this number rising to approximately 522 in 2012.
Similar developments took place in South Korea, where the number of clinical trials increased from less than 11 to al-
most 478, and Israel where an increase from approximately 29 clinical trials in 2002 to almost 357 trials in 2012 can
be observed.
Organizations based in Brazil and Taiwan have been able to increase their participation in international clinical
trials considerably as well. However, these countries show a decline in the number of weighted clinical trials in recent
years. Facilities located in India were also more frequently involved in clinical trials. After a considerable increase
from approximately 9 trials in 2002 to slightly more than 100 trials in the year 2006, their number remains quite sta-
ble around 130 over time, with a slight decrease to approximately 119 clinical trials in the year 2012. The remaining
nontraditional countries also show an increase which is followed by a rather stable number of trials in the past years
of the observation period.
Next, we use regression models to explore the development of trials over time. The dependent variable, weighted
clinical trials per country (Weighted Trialsit), is zero for a considerable number of cases and roughly continuously dis-
tributed over positive values. Since linear models do not fully account for this data structure, we use Tobit regression
models with clustered standard errors on the country level. Since the objective of this study is to map the changing
geography of clinical research, we use time (T) as an independent variable to test time effects. The year 2002 serves
as the base year with T¼ 1. We use the squared time period (T2) to take nonlinear relationships between time and
the involvement of nontraditional countries in clinical activities into account.
Further, we account for country-specific supply-side factors and demand-side factors by using data provided by
the World Bank. With respect to the supply-side, we use the natural logarithm of countries’ scientific and engineering
journal articles as a proxy for countries’ scientific basis (SciTec Articlesit). This variable refers to journal articles pub-
lished in the fields of physics, biology, chemistry, mathematics, clinical medicine, biomedical research, engineering
and technology, or earth and space sciences per year. Price and cost differences among countries are taken into ac-
count by using the GDP-related purchasing power parity conversion factor, i.e., the number of a country’s local cur-
rency units required to buy the same amounts of goods and services in the corresponding country as 1 US dollar
would buy in the United States (Price Levelit).
With respect to the demand-side, we use the natural logarithm of the total population as proxy for the size of a
market (Populationit). According to the World Bank, Populationit represents counts of all residents of a country re-
gardless of legal status or citizenship except for refugees not permanently settled in the country of asylum.
Figure 2. Share of selected nontraditional countries in conducting weighted clinical trials.
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Furthermore, we use the natural logarithm of the GDP per capita (GDPit) in current US dollars as well as the total of
public and private health expenditures as a percentage of GDP (Health Expendituresit) as further variables connected
to the demand-side. Total health expenditures include the provision of preventive and curative health services, family
planning activities, nutrition activities, and emergency aid designated for health.
Net inflows of foreign direct investments in billion US dollars (Net FDIit) are used as a further control variable to
account for the attractiveness of the economy and its involvement in international business activities.
Table 1, depicts several subsamples of trials: Model 1 reports results including all clinical trials, Model 2 repre-
sents the subset of trials sponsored by industry, whereas Models 3–8 take into account the clinical phases. In line
with the descriptive analyses, our regression analyses indicate that particularly the number of weighted Phase 2 and
Phase 3 trials increases over time. In terms of the functional form, we detect an inverted U-shaped relationship be-
tween time and the number of weighted clinical trials conducted in nontraditional countries. The number of weighted
Phase 2 and Phase 3 clinical trials increased from 2002 to 2005 and shows a slight tendency to decrease thereafter.
The size of the scientific basis of a country in terms of its scientific and engineering articles appears to be highly sig-
nificantly correlated with the number of clinical trials in all subsamples. Hence, countries with a more sophisticated
scientific basis are particularly equipped to conduct clinical trials. We do not find robust support for cost arguments
influencing the number of clinical trials in nontraditional countries. Nevertheless, the price indicator is positively
related to the overall number of weighted clinical trials as well as to the number of Phase 2 and Phase 3 trials. It is,
however, not significantly related to the number of industry-sponsored trials indicating that cost-based arguments
cannot fully explain the increasing global spread of clinical research activities.
Variables related to the attractiveness of a country as a market for (Western) pharmaceuticals are particularly cor-
related with the number of later-stage trials and industry-sponsored trials. More specifically, countries with a larger
market, i.e., a larger population, a larger GDP per capita, or higher health expenditures as percentage of GDP, have
a higher number of weighted total and industry-sponsored Phase 3 trials as well as a higher number of industry-spon-
sored Phase 2 trials. Net FDI inflows are positively related to the number of industry-sponsored clinical trials and
Phase 3 trials. Lagged dependent variables are positively related to the number of clinical trials, suggesting some path
dependency in their involvement in global clinical research. These results hold for the sample of traditionally coun-
try-sponsored trials.9
Further, we use the share of a country in conducting clinical trials (Share Countryit) to analyze the changing rela-
tive importance of nontraditional countries. This variable is computed by dividing the number of weighted clinical
Figure 3. Share of Phase 3 clinical trials in selected nontraditional countries.
9 These results are robust to the inclusion of WHO Regions as well as World Bank income groups as additional control
variables.
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trials in country i in a specific start year by the total number of all clinical trials conducted in traditional and nontrad-
itional countries that started in that year.
Figure 2 suggests that nontraditional countries have gained importance as locations for clinical trials, though their
share is still low.10 China, South Korea, and Israel started with a share of less than 1% in 2002 and increased to
more than 3% in the case of China and South Korea and more than 2.5% in the case of Israel. Again, Taiwan and
Brazil show a sharp decline in their share of weighted clinical trials due to the decrease in their number of weighted
clinical trials in recent years. Initially, India can increase its share of clinical trials from 0.2% in 2002 to slightly more
than 1% in 2007. Since then, the Indian share has decreased to 0.83%. This development, as well as the rather stable
absolute number of weighted clinical trials, questions the importance of India as one of the main destinations for clin-
ical trial offshoring as reported in some parts of the (medical) literature (Cekola, 2007; Maiti and Raghavendra,
2007; Drabu et al., 2010; Gupta and Padhy, 2011).
In addition, we use fractional logit regressions to analyze the share of countries in conducting weighted clinical
trials (Share Countryit). Papke and Wooldridge (1996) propose models for fractional response if the dependent vari-
able is bounded between 0 and 1 and is continuous within these boundaries. The proposed fractional response model
ensures that the predicted values of the dependent variable are within the unit interval and do not require adjustments
if the extreme values of the dependent variable, 0 or 1, are observed (Papke and Wooldridge, 1996). The proposed
method uses quasi-maximum likelihood estimation to obtain robust estimators of the conditional mean and satisfac-
tory efficiency properties. In many economic applications, the mean function takes the logistic form, a variant of the
model that has been labeled fractional logit. We employ the fractional logit model with clustered standard errors on
the country level.
Our fractional logit regressions in Table 2 indicate that nontraditional countries for clinical research have
increased their share in clinical trials particularly in Phase 2 and in industry-sponsored Phase 3 trials. However, the
results suggest that the share of nontraditional countries in these subsamples has decreased slightly since 2005. In line
with our findings related to the weighted number of clinical trials per country, we find that a country’s scientific basis
is positively related to its share of clinical research across different phases. With the exceptions of total trials and
Phase 2 trials, price-level factors are not associated with the share of clinical trials conducted in nontraditional coun-
tries. Demand-related factors such as the population size, the GDP per capita, and health expenditures as percentage
of GDP are related to the share of industry-sponsored Phase 3 trials. Net inflows of FDIs are negatively related to the
Figure 4. Share of industry-sponsored Phase 3 clinical trials in selected nontraditional countries.
10 The observed increase in the share for the different countries is in line with a decreasing share of the United States
from around 50% in 2002 to less than 40% in 2012. However, the United States remains the dominating country in clin-
ical research. The share of other leading traditional trial locations, i.e., countries particularly located in Western
Europe, rests quite stable between 2% (United Kingdom) and 5% (Canada).
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share of a country in the samples of all trials, and in Phase 3 trials irrespective of the type of sponsor. Lagged depend-
ent variables are positively related to the share of countries conducting clinical trials for all different specifications of
the dependent variable. The results for the sample of clinical trials sponsored by traditional countries are largely in
line with the results described above.
Overall, these findings suggest that at least some nontraditional trial countries have managed to narrow the gap
to the leading countries in clinical research with respect to the absolute number as well as to the share of (weighted)
clinical trials. These descriptive results are largely in line with the findings presented by Thiers et al. (2008) who re-
port that most nontraditional countries are small players but, as a group, host 17% of all active recruiting clinical
trial facilities. The observed expansion of clinical trials in many nontraditional countries is in line with a decreasing
share of the United States, whereas Western European countries have kept their share in terms of weighted clinical
trials quite stable.
4.2 Overemphasis of supply-side arguments: limited increase of Phase 3 trials
Prior research supposes that clinical trial sponsors offshore trials that are predominantly conducted for data gener-
ation purposes, as these are typically the most expensive ones (DiMasi et al., 2003; Azoulay, 2004; Howells et al.,
2008; Rafols et al., 2014). If this holds true, we would see that particularly Phase 3 trials which need a high number
of enrolled subjects are increasingly conducted in nontraditional countries where there is a high availability of treat-
ment naı¨ve subjects. Hence, we explore the relative frequency of different phases in the countries over time. In doing
Table 3. Fractional logit regressions for the share of clinical trials in specific phases
Sample (1) (2) (3) (4) (5) (6)
Phase 1 Phase 1 industry-
sponsored
Phase 2 Phase 2 industry-
sponsored
Phase 3 Phase 3 industry-
sponsored
Dependent variable: Share Phase j it
T 0.3115 0.0332 0.4292*** 0.3191* 0.1197 0.2801*
(0.3397) (0.3953) (0.1627) (0.1843) (0.1394) (0.1493)
T2 0.0427 0.0170 0.0381** 0.0189 0.0234* 0.0396***
(0.0321) (0.0367) (0.0159) (0.0174) (0.0135) (0.0137)
SciTec Articlesit 0.1411 0.3677** 0.1578*** 0.2243*** 0.0004 0.0341
(0.1327) (0.1829) (0.0560) (0.0758) (0.0616) (0.0718)
Price Levelit 0.4939 1.3587 0.3974 0.7652 0.2546 0.4812
(0.9204) (1.4733) (0.5407) (0.5171) (0.5238) (0.5781)
Populationit 0.1954 0.3225 0.1445* 0.2791*** 0.0292 0.0218
(0.1767) (0.2236) (0.0748) (0.1079) (0.0791) (0.0950)
GDPit 0.4504*** 0.4791 0.1219 0.5187*** 0.0444 0.1929
(0.1725) (0.2996) (0.0950) (0.1566) (0.0876) (0.1299)
Health Expendituresit 0.0580 0.1376 0.0174 0.0118 0.0995** 0.0851*
(0.0735) (0.1108) (0.0389) (0.0581) (0.0420) (0.0471)
Net FDIit 0.0071 0.0044 0.0003 0.0030 0.0006 0.0050**
(0.0056) (0.0061) (0.0025) (0.0046) (0.0024) (0.0022)
Share Phase j it-1 0.9945 2.7670** 0.5265* 0.5332 0.7717*** 0.6708***
(0.7525) (1.2081) (0.2727) (0.3840) (0.2094) (0.2516)
Constant 3.5659 3.1678 0.0283 4.9311* 1.3496 0.5364
(3.9841) (5.0979) (1.6679) (2.7290) (1.6160) (2.1419)
N 566 418 566 418 566 418
AIC 230.4934 139.1504 459.0778 368.2921 554.4061 443.1128
BIC 273.8793 179.5052 502.4637 408.6469 597.7921 483.4676
Note. Clustered standard errors in parentheses.
*P < 0.10, **P < 0.05, ***P < 0.01.
Dependent and lagged dependent variables are subset-specific.
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so, we calculate the share of a phase j in country i in a given year (Share Phase j it). We calculate this variable by
dividing the number of weighted clinical trials in a specific phase conducted in country i by the number of total
weighted clinical trials performed in country i. All clinical trial counts and shares are calculated on a yearly basis to
track changes over time.
Figure 3 depicts the share of (weighted) Phase 3 trials as a percentage of all trials conducted in specific countries
in a given start year.11 Surprisingly, our analysis does not suggest that Phase 3 trials are frequently conducted in
nontraditional countries. In terms of China, the share of (weighted) Phase 3 trials decreased from around 29% in
2002 to approximately 19% in 2012. Similar developments can be observed for South Korea, where the share
decreased from approximately 50% to circa 15.5%, Israel showed a decrease from roughly 35% to approximately
10%, and India, which decreased from approximately 28 to 20%. These numbers are below the share of Phase 3 clin-
ical trials in all clinical trials in most traditional countries, which equaled 20–30%. As shown in Figure 4, the share
of Phase 3 trials among the industry sponsored trials usually exceeds the overall share of Phase 3 trials but remains
rather stable or even decreases over time for all nontraditional countries.12 Even in Brazil, where approximately 60%
of industry-sponsored trials refer to Phase 3, the share remained rather stable since 2006. These results do not suggest
that countries with considerable cost advantages, as compared to the United States, show a relatively large increase
in Phase 3 clinical trials. Moreover, the development of the share of Phase 3 clinical trials in these countries does not
Table 4. Most frequently addressed disease areas in selected nontraditional countries
Country 2002–2004 2010–2012
Brazil Pathological conditions, signs, and symptoms;
cardiovascular diseases; respiratory tract
diseases
Pathological conditions, signs and symptoms;
cardiovascular diseases; respiratory tract
diseases
China Pathological conditions, signs, and symptoms;
digestive system diseases; neoplasms
Neoplasms; digestive system diseases; patho-
logical conditions, signs and symptoms
India Pathological conditions, signs, and symptoms;
neoplasms; respiratory tract diseases
Pathological conditions, signs, and symptoms;
digestive system diseases; nutritional and
metabolic diseases
Iran Islamic Republic Eye diseases; musculoskeletal diseases; patho-
logical conditions, signs, and symptoms
Pathological conditions, signs, and symptoms;
stomatognathic diseases; cardiovascular
diseases
Israel Mental disorders; pathological conditions,
signs, and symptoms; cardiovascular diseases
Pathological conditions, signs, and symptoms;
nervous system diseases; mental disorders
South Korea Neoplasms; digestive system diseases; mental
disorders
Neoplasms; pathological conditions, signs, and
symptoms; cardiovascular diseases
Mexico Nutritional and metabolic diseases; endocrine
system diseases; neoplasms
Pathological conditions, signs, and symptoms;
nutritional and metabolic diseases; respira-
tory tract diseases
Poland Cardiovascular diseases; neoplasms; respiratory
tract diseases
Pathological conditions, signs, and symptoms;
cardiovascular diseases; neoplasms
Russia Neoplasms; mental disorders; cardiovascular
diseases
Cardiovascular diseases; pathological condi-
tions, signs, and symptoms; neoplasms
Taiwan Neoplasms; pathological conditions, signs, and
symptoms; cardiovascular diseases
Pathological conditions, signs, and symptoms;
neoplasms; cardiovascular diseases
Thailand Virus diseases; immune system diseases; eye
diseases
Pathological conditions, signs, and symptoms;
virus diseases; immune system diseases
The United States Neoplasms; mental disorders;pathological con-
ditions, signs, and symptoms
Neoplasms; pathological conditions, signs, and
symptoms; cardiovascular diseases
11 Consequently, a decreasing share of Phase 3 trials in a country implies that the country conducts more trials in other
phases.
12 Iran is to some extent an exception because only very few industry-sponsored trials are conducted in Iran.
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differ substantially from the development observed in countries that have a lower cost advantage to the United
States, such as Poland, Israel, or Taiwan. Russia might be an exception to some extent, since the share of Phase 3 clin-
ical trials remains rather stable and showed an increase in recent years. This may have been driven by the relatively
low cost of conducting clinical research, which equals around 40% of the US cost (Agalew, 2013).
In contrast and quite surprisingly, most nontraditional countries increased the share of Phase 1 and Phase 2 clin-
ical trials. In the case of China, the share of Phase 1 trials rose from 7% in 2002 to approximately 11.5% in 2012,
and the share of Phase 2 trials increased from around 23.5 to 25.6%. Similarly, South Korea increased the share of
Phase 1 trials from 1 to approximately 15% and their share of Phase 2 trials from almost 13 to 18%. India showed a
growth of the share of Phase 1 studies from 2 to more than 23% and a growth of Phase 2 studies from 3 to 20%. In
contrast, the share of Phase 1 studies among the total clinical trials conducted in Israel remained rather constant with
a value of 8.6% in 2002 and 7.5% in 2012. The share of Phase 2 trials in Israel decreased from 27 to 13%. For most
traditional countries, the share of Phase 1 trials is between 10 and 20%, whereas the share of Phase 2 trials varies
around 20%. Overall, an increasing share of Phase 1 and Phase 2 trials can also be found for the trials sponsored by
organizations from traditional countries and for industry-sponsored trials.
The corresponding regression results suggest that particularly the share of Phase 2 trials and industry-sponsored
Phase 3 trials in nontraditional countries have been increasing over time. Again, we find an inverted U-shaped rela-
tionship Models (3) and (4) in Table 3, indicating that the share of the corresponding trial type increased up to 2005
and has been decreasing thereafter. In addition, the results reveal that particularly a country’s scientific basis is linked
to its share of Phase 2 trials irrespective of the type of sponsor. In contrast, cost- or demand-related factors have ei-
ther no, e.g., price level and health expenditures or a negative association, e.g., population size, to the share of Phase
2 trials in nontraditional countries. We find, however, a significant and positive relationship between the share of in-
dustry-sponsored Phase 3 trials and countries’ health care expenditures.
Despite the slight increase in industry-sponsored Phase 3 trials over time, our results do not support the widely
held notion that the shift of clinical research activities to nontraditional clinical research countries is mostly driven by
cost arguments. Instead, our results indicate that nontraditional countries’ scientific and technological knowledge
bases support these countries in conducting knowledge-intense clinical trials.
4.3 Convergence in countries’ clinical trial profiles
The following section explores whether the clinical research profiles of nontraditional countries are showing an
increasing similarity to the US profile, or whether these countries are addressing diseases which are rather country-
specific. In Table 4, we present a detailed overview concerning the most frequently addressed disease areas based on
three-digit MeSH tree numbers in the main nontraditional countries. Surprisingly, a rather general MeSH tree
Figure 5. Development overlap between the United States and selected nontraditional countries.
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number “Pathological Conditions, Signs and Symptoms” referring to “abnormal anatomical or physiological condi-
tions and objective or subjective manifestations of disease, not classified as disease or syndrome” has been increas-
ingly used to characterize clinical research in nontraditional countries. The increasing importance of this rather
general category may partly explain the converging trend toward clinical research conducted in the United States for
many countries. However, Table 4 also suggests that nontraditional countries are able to address disease areas that
are of particular importance in their local environment. In particular, infectious diseases as well as nutritional and
metabolic diseases are among the most important causes of death in low- and lower middle-income countries
(Mathers et al., 2009; World Health Organization, 2014). Our results indicate that countries like Brazil, India,
Mexico, and Thailand emphasize these disease areas in their clinical research activities.
The World Health Organization (2014) points out that cardiovascular diseases, neoplasms/cancer and nervous
system diseases such as Alzheimer’s disease are the most important causes of death in high-income countries. Table 3
shows that higher-income countries among the nontraditional countries for clinical research conduct clinical research
in these areas. Among the main nontraditional countries, Israel, South Korea, Poland, Russia, and Taiwan can be
seen as higher-income countries addressing these disease groups in their clinical research. China’s classification as an
“upper middle income” country by the World Bank may explain the importance of neoplasms in its clinical research
to some extent.
In summary, our exploration indicates that nontraditional countries address MeSH tree numbers that are also ad-
dressed in the US clinical research more frequently. Thus, they are addressing diseases with either a worldwide preva-
lence or diseases with a particular importance for higher-income countries. Nevertheless, some lower- and middle-
income countries also manage to address disease areas that are important causes of death in their income group.
Hence, at least to some extent, these countries address local health problems.
We aim to further explore heterogeneity in the specialization of countries as well as similarity to the United States
as the dominant location for conducting clinical research, one of the largest markets for pharmaceuticals worldwide
and one of the leading countries in the field of biomedical research. In doing so, we use the MeSH to analyze coun-
tries’ specialization patterns in conducting clinical trials based on conditions, indications, treatments, and pathogens.
We compare countries’ specialization patterns by building upon prior work by Onal Vural et al. (2013) and Azoulay
et al. (2006) who developed a measure of the scientific similarity between researchers based on the degree of overlap
in keywords attached to their publications. In line with their work, our measure accounts for similarity in the clinical
research profiles of a nontraditional country i and the United States based on MeSH tree numbers:
Overlapi to US in t ¼ Count of overlappingMESH tree numbers
Count of MeSH tree numbers associated with i
:
Figure 6. Overlap share between the United States and selected nontraditional countries (only industry-sponsored clinical trials)
over time.
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We calculate the Overlapi to US in t on a yearly basis to track changes in countries’ clinical research profiles over
time. In doing so, we count the number of unique MeSH tree numbers that occur in clinical trials which are con-
ducted in country i and which occur at the same time in clinical trials exclusively conducted in the United States, i.e.,
all trial sites are located in the United States. This count is divided by the total number of unique MeSH tree numbers
found in clinical trials conducted in country i.
The overlap measure ranges from 0 to 1, with 0 indicating that no MeSH tree numbers addressed in country i
overlap with MeSH tree numbers addressed in the United States. An overlap measure equal to 1 stands for a complete
overlap in MeSH tree numbers. Consequently, a low overlap measure indicates substantial differences in the condi-
tions, indications, treatments, and pathogens addressed in clinical trials conducted in country i compared to the
United States, whereas a high overlap measure suggests a high level of similarity in the clinical research profiles of
country i and the United States. It should be noted that the measure is not symmetric but depends on the country
chosen as a reference in the denominator. Moreover, and in contrast to other similarity measures, the overlap meas-
ure leads to meaningful results even if the benchmark country has a dominant position and conducts clinical trials
related to most MeSH tree numbers.
In the following we provide an example for the calculation of the overlap measure. Suppose that clinical trials
conducted in the United States contain the different MeSH tree numbers C04 (neoplasms), C05 (musculoskeletal dis-
eases), and C14 (cardiovascular diseases), whereas clinical trials conducted in country i report the MeSH tree
Table 5. Fractional logit regressions for nontraditional countries profiles’ overlap to the United States
Sample (1) (2) (3) (4) (5) (6) (7) (8)
Full Industry-
sponsored
Phase 1 Phase 1
industry-
sponsored
Phase 2 Phase 2
industry-
sponsored
Phase 3 Phase 3
industry-
sponsored
Dependent variable: Overlapi to US in t
T 0.1063 0.2867** 0.3210 1.8540*** 0.2067 0.2877 0.2948* 0.3613**
(0.1884) (0.1463) (0.5409) (0.6661) (0.2664) (0.2053) (0.1620) (0.1477)
T2 0.0063 0.0257* 0.0264 0.1545*** 0.0188 0.0263 0.0175 0.0238*
(0.0184) (0.0135) (0.0486) (0.0582) (0.0245) (0.0195) (0.0149) (0.0137)
SciTec Articlesit 0.0330 0.0651 0.2788 0.1779 0.1517 0.1224 0.1606*** 0.1598***
(0.0678) (0.0632) (0.1801) (0.1545) (0.1064) (0.0796) (0.0549) (0.0422)
Price Levelit 0.2909 1.5060** 1.1911 1.3068 1.3983 1.8819** 0.1743 0.6552
(0.5895) (0.7425) (1.6123) (1.7368) (0.9504) (0.9419) (0.5506) (0.4522)
Populationit 0.1083 0.0658 0.4533** 0.2097 0.0260 0.0533 0.2021*** 0.1158*
(0.1081) (0.0845) (0.2071) (0.2204) (0.1373) (0.0973) (0.0759) (0.0678)
GDPit 0.1650* 0.5268*** 0.3053 0.1694 0.2913 0.2894 0.4048*** 0.3679**
(0.0991) (0.1370) (0.3216) (0.4051) (0.1980) (0.2407) (0.0960) (0.1479)
Health Expendituresit 0.0033 0.0845 0.0418 0.1532 0.0558 0.1182* 0.0167 0.0393
(0.0463) (0.0555) (0.0811) (0.1318) (0.0658) (0.0639) (0.0436) (0.0325)
Net FDIit 0.0001 0.0011 0.0010 0.0059 0.0011 0.0016 0.0019 0.0008
(0.0021) (0.0022) (0.0033) (0.0039) (0.0035) (0.0022) (0.0021) (0.0022)
Overlapi to US in t-1 2.1861*** 0.7849** 1.1382** 0.8088 0.6143* 0.7720*** 0.9838*** 1.0886***
(0.3608) (0.3824) (0.5105) (0.6296) (0.3306) (0.2640) (0.3048) (0.3223)
Constant 0.2256 3.4773* 8.4545* 0.0027 2.3387 2.7197 4.7425*** 3.2344*
(2.1116) (1.9874) (4.6766) (8.0475) (3.2573) (2.8827) (1.5368) (1.8295)
N 556 414 133 82 314 259 409 333
AIC 324.6233 331.2875 125.7455 91.9782 282.0538 263.9782 398.0347 340.4711
BIC 367.8310 371.5461 154.6489 116.0454 319.5477 299.5465 438.1718 378.5525
Note. Clustered standard errors in parentheses.
*P < 0.10, **P < 0.05, ***P < 0.01.
Dependent and lagged dependent variables are subset-specific.
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numbers C03 (parasitic diseases) and C14. Hence, the number of overlapping MeSH tree numbers equals 1 (C14)
and the count of country i’s MeSH tree numbers equals 2 so that the Overlapi to US in t ¼ 1=2.
At first sight, Figure 5 suggests a general trend to convergence, but a closer look illustrates some differences in the
development of the main nontraditional clinical trial countries’ clinical research profiles and the clinical research pro-
file of the United States. While some countries increasingly conduct clinical trials that address conditions, indications,
treatments, and pathogens that are addressed in clinical trials exclusively conducted in the United States, other coun-
tries developed a clinical research profile that is less similar to the United States’ profile.
China, as the nontraditional country with the highest number of clinical trials, increased its overlap from 0.67 in
2002 to 0.87 in 2011, indicating that China’s clinical research profile shows a growing similarity to the US profile.
However, the overlap decreased again slightly to 0.82 in 2012. Several other countries show an increasing or rather
stable similarity to the US profile particularly in the years after 2004, such as Brazil, Israel, Poland, Mexico, Poland,
Russia, and Thailand. Remarkably, South Korea, which had exclusively addressed MeSH tree numbers that were
also addressed in the United States in 2002 decreased its overlap to 0.89 in 2012. Taiwan also shows a tendency to
address more MeSH tree numbers that are not addressed in the United States, since its overlap decreased from ap-
proximately 0.95 in 2002 to approximately 0.9 in 2012. After an initial decrease from 0.96 in 2002 to 0.8 in 2004,
India’s clinical research profile became more similar to the US profile once more with an overlap of 0.9 in 2006.
However, India has decreased its similarity to the United States in subsequent years as indicated by an overlap of 0.8
in 2012.
The extent to which clinical trial profiles become more alike to the profile of the United States may depend on the
sponsors of clinical trials. Biopharmaceutical companies, particular those based in the traditional (Western) industry
centers, may prioritize clinical testing of drug candidates that address diseases or conditions with a worldwide preva-
lence and a high potential demand (in Western markets), such as cancer, cardiovascular diseases, and nervous system
diseases, e.g., those closely related to aging populations. Biopharmaceutical companies located in nontraditional
countries may follow a rather similar strategy and address these worldwide diseases due to the larger market size as
compared to diseases that are specific to their countries of origin or due to opportunities to develop generic drugs.
On the contrary, nontraditional countries’ governments and nonprofit organizations may be interested in the devel-
opment of treatments and new medications against local health problems, such as bacterial infections, virus, or para-
sitic diseases that are rarely addressed by (Western) biopharmaceutical companies. Moreover, local firms may have
access to locally bounded knowledge which provides them with a unique competitive advantage in addressing
country-specific diseases.
Concentrating on clinical trials that have been sponsored by the biopharmaceutical industry, the patterns pre-
sented in Figure 6 suggest that nontraditional countries’ clinical research profiles converge to the profile of the
United States over time. Although industry-sponsored trials show a higher initial level of dissimilarity in 2002, only
minor differences in the overlap measure of industry-sponsored and all clinical trials can be observed for the main
nontraditional countries in 2012. The overlap measure referring to industry-sponsored trials increased considerably
for some countries, e.g., for China from 0.59 in 2002 to 0.86 in 2012, for India from 0.62 to 0.81, or South Korea
from 0.68 to 0.84. For some other countries, the decrease is more moderate, e.g., Brazil’s and Israel’s overlap meas-
ure decreased from 0.77 in 2002 to 0.83 in 2012 and from 0.76 to 0.79, respectively. To some degree, Iran can be
considered an exception, since the country hosts only very few clinical trials sponsored by the biopharmaceutical
industry.
The results of the fractional logit regressions investigating whether the overlap between the United States and
nontraditional clinical trial countries’ MeSH tree numbers changed over time are presented in Table 5. The explor-
ation of several subsamples of clinical trials depending on sponsor and trial characteristics reveals nuanced patterns
of development. We do not find support for a changing overlap over time in the full sample. However, the overlap to
the United States changes particularly for industry-sponsored trials. More specifically, we find a U-shaped relation-
ship between the time T and the overlap of nontraditional countries clinical research profiles to the US profile for all
industry-sponsored trials as well as for Phase 3 industry-sponsored trials. While the similarity to the United States
decreased for the sample of industry-sponsored trials until 2006 or 2007 and increased thereafter again, it decreased
in case of industry-sponsored Phase 3 trials until 2009 and showed an increase thereafter. Contrary to these results,
we find an inverted U-shaped relationship between T and the overlap for Phase 1 industry-sponsored trials, suggest-
ing that in this category clinical trial profiles initially become more similar before turning more diverse in the period
including and after 2005. For the subsample of Phase 3 clinical trials, we find a linearly decreasing similarity over
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time. Countries with a high population and a high GDP per capita, as indicators for market attractiveness, show a
higher overlap for Phase 3 trials and industry-sponsored Phase 3 trials. In addition, GDP per capita is positively
related to the overlap in the full sample and in the sample of industry-sponsored trials. The number of countries’ sci-
entific articles is negatively related to the overlap measure for Phase 3 and industry-sponsored Phase 3 trials, while
the price-level indicator is negatively associated with the overlap for industry-sponsored trials and Phase 2 industry-
sponsored trials.
Our regression analysis points to a rather limited convergence of nontraditional countries clinical research profiles
to the profile of the United States based on MeSH tree numbers.13 With respect to knowledge transfer arguments,
nontraditional countries might have learnt through the increasing number of trials they have hosted over time to ad-
dress conditions, diseases, treatments, or pathogens that are of local importance, at least in Phase 3 projects.
Particularly, countries with a strong scientific base are able to conduct late-stage clinical research activities that do
not correspond to US clinical trials. These developments toward a more independent clinical research profile are to
some extent counterbalanced by variables related to market size and attractiveness that stimulate clinical research
activities similar those conducted in the United States.
The results for clinical trials sponsored by organizations based in traditional countries are rather similar to those
discussed above.
5. Discussion and conclusions
There seems to be a broad consensus that clinical trials are globally migrating. However, the scant empirical attention
so far has led to contradictory views in terms of the involved countries and the underlying reasons for the globaliza-
tion of clinical research. Building on the concept of national innovative capacity (Furman et al., 2002), we explored
the changing geographical patterns of clinical research activities and its drivers based on a comprehensive data set of
clinical trials registered in the years from 2002 to 2012.
Our empirical analyses suggest that nontraditional countries are often increasingly involved not only in data-
intense but also in knowledge-intense clinical research activities irrespective of the type of sponsor. Particularly the
leading nontraditional countries, e.g., China, South Korea, and Israel, increased the absolute number of trials as well
as their share in global clinical trials, while the dominant position of the United States has been (slightly) weakened.
Some countries, such as India, that are often named as important locations for clinical trials are not involved as much
as anecdotal evidence has suggested (Glickman et al., 2009).
So far, the mounting involvement of nontraditional countries in offshored R&D activities is widely attributed to
cost reductions and efficiency improvements in data generation trials (Glickman et al., 2009; Gupta and Padhy,
2011). Contrary to this widely held belief, our results do not indicate that cost differences are the main reasons for
the involvement of nontraditional countries in clinical research. Beyond the specific setting of the geography of clin-
ical research, this result questions to some extent the importance of cost advantages for R&D offshoring in general
(Farrell, 2005; Demirbag and Glaister, 2010). Instead, our findings reveal that nontraditional countries’ scientific
and technological knowledge bases tend to drive the amount of clinical trials performed in these countries. This result
supports the view that host countries’ knowledge base as well as the availability of science and engineering talent de-
termines countries’ attractiveness for offshored R&D services (Manning et al., 2008; Lewin et al., 2009).
Furthermore, our empirical results suggest that differences in countries’ national innovative capacity lead to con-
siderable variation in the direction of their R&D activities in terms of whether their fields of research are locally or
globally relevant. On the one hand, for knowledge-intense early stage trials, we find a tendency that nontraditional
countries are increasingly addressing disease areas that are conducted at the same time in the United States. On the
other hand, nontraditional countries have been able to increasingly address local health problems in late-stage clinical
research. An advanced science and technology base enables nontraditional countries to benefit from offshored R&D
activities through knowledge spillovers and knowledge transfer (Hu et al., 2005) and to perform clinical research
activities that correspond to local health problems.
13 It should be noted that our database accounts for a rather conservative estimation of the amount of clinical trials ad-
dressing disease areas with a local prevalence, since these trials may not necessarily be registered in
ClinicalTrials.gov.
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In addition, and consistent with the literature (Gassmann and Han, 2004), our findings indicate that, across
nontraditional countries, demand-side factors support the involvement in late-stage clinical trials which have a rather
limited potential for knowledge spillovers and transfer. More attractive markets support clinical research activities
directed toward global rather than local health problems. The consequences for the inhabitants of nontraditional
countries are, however, ambiguous. On the one hand, they may benefit from the improved safety and efficacy due to
drug development that takes local specificities into account (Kremer, 2002). On the other hand, the negligence of
local health problems in (Western) pharmaceutical R&D may continue.
These results are highly relevant and have important implications for innovation and pharma-economics scholars,
as they provide insights into the extent of internationalization of clinical research and the involvement of particular
countries. They go beyond many existing studies by challenging widely shared beliefs claiming that predominantly
data-intense development activities are relocated to nontraditional countries due to cost advantages. Instead, our re-
sults suggest that knowledge-intense development activities are also increasingly conducted in nontraditional
countries.
For policy makers in nontraditional countries, our study suggests that investments into countries’ science and
technology base support their attractiveness for knowledge-intense trials that are associated with a higher potential
for knowledge transfer and learning, thus supporting the development of the domestic biopharmaceutical industry.
At the same time, these investments enable countries to address local health problems, at least in late-stage clinical
research.
For practitioners in the biopharmaceutical industry, the article provides a detailed description of the changing
geography of clinical research and its drivers that can be helpful for future decisions about the location of clinical
trials.
We see our exploratory analysis as the first step of a broader research agenda to deepen our understanding of the
involvement of nontraditional countries in international R&D activities, the drivers of this development, and its con-
sequences, particularly but not exclusively with respect to clinical research activities. First, the mechanisms of know-
ledge spillovers and knowledge transfer through offshored R&D activities such as clinical trials need to be
thoroughly examined. Second, there is a lack of empirical investigations evaluating the consequences of offshored
R&D activities for serving the needs of nontraditional countries and their populations such as the availability, safety,
and efficacy of new or improved medications. Third, we need a detailed understanding of whether offshored develop-
ment activities, such as late-stage clinical trials, can stimulate the development of the domestic knowledge base and
support R&D activities with a domestic relevance.
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Appendix
Table A1. Accumulated clinical trials per country (2002–2012) (clinical trial counts are weighted by the number of involved
countries)
Sr. No. Country All trials Phase 1 Phase 2 Phase 3 Country type
1 The United States 59,921.38 12,274.36 17,399.21 6,597.01 Traditional
2 Canada 6500.78 828.17 1588.96 1252.34 Traditional
3 Germany 5351.99 768.77 1299.15 1053.79 Traditional
4 France 5144.44 427.42 1095.56 1102.27 Traditional
5 United Kingdom 3978.65 858.17 928.24 660.24 Traditional
6 China 2970.51 298.44 641.73 650.11 Nontraditional
7 South Korea 2840.04 327.21 587.65 448.51 Nontraditional
8 Israel 2760.17 288.75 482.03 273.74 Nontraditional
9 Italy 2577.80 140.75 678.57 650.42 Traditional
10 Denmark 2306.52 140.56 331.18 249.86 Traditional
11 The Netherlands 2192.11 294.53 401.29 376.58 Traditional
12 Japan 2084.91 449.20 516.13 707.00 Traditional
13 Spain 1974.53 180.54 531.19 387.72 Traditional
14 Taiwan 1946.67 118.19 265.71 227.12 Nontraditional
15 Brazil 1915.50 146.27 286.56 475.19 Nontraditional
16 Belgium 1636.33 303.29 395.63 261.07 Traditional
17 Switzerland 1550.15 188.24 295.63 203.32 Traditional
18 Australia 1344.03 285.01 366.70 296.53 Traditional
19 Sweden 1313.11 174.00 252.45 190.57 Traditional
20 Norway 1143.54 78.04 205.38 149.73 Traditional
21 India 1093.10 217.35 212.80 283.87 Nontraditional
22 Austria 1040.74 90.62 226.22 196.93 Traditional
23 Finland 672.59 53.73 119.45 126.74 Traditional
24 Thailand 657.74 49.49 133.96 158.38 Nontraditional
25 Poland 590.49 42.38 164.71 194.06 Nontraditional
26 Mexico 545.05 57.68 153.70 169.56 Nontraditional
27 Singapore 533.01 158.08 113.76 67.10 Nontraditional
28 Iran Islamic Republic 484.35 81.00 177.50 117.22 Nontraditional
29 Greece 484.07 18.32 107.43 86.82 Nontraditional
30 Russia 436.43 35.67 144.31 159.22 Nontraditional
Table A2. Correlations
Variable (1) (2) (3) (4) (5) (6) (7)
(1) T 1.0000
(2) SciTec Articlesit 0.0498 1.0000
(3) Price Levelit 0.0844** 0.1896*** 1.0000
(4) Populationit 0.0288 0.5649*** 0.0330 1.0000
(5) GDPit 0.1985*** 0.3683*** 0.6762*** 0.3488*** 1.0000
(6) Health Expendituresit 0.1251*** 0.0112 0.0131 0.1221*** 0.0477 1.0000
(7) Net FDIit 0.1084*** 0.4656*** 0.0159 0.3432*** 0.1995*** 0.0495 1.0000
Note. *P < 0.05, **P < 0.01, ***P < 0.001.
Although some correlation may seem quite high, variance inflation factors do not suggest multicollinearity.
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Table A3. Summary statistics
Variable Sample N Mean SD Minimum Maximum
Weighted Trialsit Full 1661 13.4719 48.7690 0.0000 553.6893
Industry-sponsored 1661 4.4469 13.6722 0.0000 164.4452
Phase 1 1661 1.3007 5.6466 0.0000 75.2583
Phase 1 industry-sponsored 1661 0.6461 3.5663 0.0000 63.5472
Phase 2 1661 2.7738 9.8228 0.0000 142.6488
Phase 2 industry-sponsored 1661 1.0803 3.2332 0.0000 34.4322
Phase 3 1661 2.8828 8.8544 0.0000 120.7325
Phase 3 industry-sponsored 1661 1.5836 4.6172 0.0000 50.2564
Share Countryit Full 1172 0.0016 0.0041 0.0000 0.0366
Industry-sponsored 1172 0.0005 0.0012 0.0000 0.0108
Phase 1 1172 0.0009 0.0029 0.0000 0.0329
Phase 1 industry-sponsored 1172 0.0004 0.0018 0.0000 0.0282
Phase 2 1172 0.0013 0.0036 0.0000 0.0443
Phase 2 industry-sponsored 1172 0.0005 0.0012 0.0000 0.0099
Phase 3 1172 0.0022 0.0052 0.0000 0.0577
Phase 3 industry-sponsored 1172 0.0012 0.0027 0.0000 0.0240
Share Phase 1 it Phase 1 1172 0.0635 0.1444 0.0000 1.0000
Phase 1 industry-sponsored 872 0.0559 0.1426 0.0000 1.0000
Share Phase 2 it Phase 2 872 0.1933 0.2365 0.0000 1.0000
Phase 2 industry-sponsored 872 0.2368 0.2805 0.0000 1.0000
Share Phase 3 it Phase 3 872 0.2968 0.2992 0.0000 1.0000
Phase 3 industry-sponsored 872 0.4158 0.3335 0.0000 1.0000
Overlapi to US in t Full 1155 0.8747 0.1969 0.0000 1.0000
Industry-sponsored 867 0.7680 0.2484 0.0000 1.0000
Phase 1 428 0.7576 0.3150 0.0000 1.0000
Phase 1 industry-sponsored 272 0.6457 0.3318 0.0000 1.0000
Phase 2 734 0.7478 0.3010 0.0000 1.0000
Phase 2 industry-sponsored 570 0.6510 0.3040 0.0000 1.0000
Phase 3 874 0.6137 0.2914 0.0000 1.0000
Phase 3 industry-sponsored 704 0.4786 0.2829 0.0000 1.0000
T Full 1661 6.0000 3.1632 1.0000 11.0000
SciTec Articlesit Full 1083 4.3973 2.4329 2.3026 11.2121
Price Levelit Full 1452 0.4884 1.1368 0.1410 43.1612
Populationit Full 1595 15.8390 1.8273 10.3937 21.0239
GDPit Full 1504 7.8857 1.4605 4.6823 12.1751
Health Expendituresit Full 1360 6.0086 2.2787 1.1215 22.1866
Net FDIit Full 1486 4.5875 16.7515 20.9335 280.0720
310 C. Haeussler and B. Rake
D
ow
nloaded from
 https://academ
ic.oup.com
/icc/article-abstract/26/2/285/3062223 by M
aynooth U
niversity user on 13 August 2019
